Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
Clearside Biomedical, Inc. (NASDAQ: CLSD) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Clearside Biomedical, Inc. (NASDAQ: CLSD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Landscape Research 2024 [Yahoo! Finance]